Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jan 23;2(1):2.
doi: 10.1186/1476-8518-2-2.

Development of a model of focal pneumococcal pneumonia in young rats

Affiliations

Development of a model of focal pneumococcal pneumonia in young rats

Richard Malley et al. J Immune Based Ther Vaccines. .

Abstract

BACKGROUND: A recently licensed pneumococcal conjugate vaccine has been shown to be highly effective in the prevention of bacteremia in immunized children but the degree of protection against pneumonia has been difficult to determine. METHODS: We sought to develop a model of Streptococcus pneumoniae pneumonia in Sprague-Dawley rats. We challenged three-week old Sprague-Dawley pups via intrapulmonary injection of S. pneumoniae serotypes 3 and 6B. Outcomes included bacteremia, mortality as well histologic sections of the lungs. RESULTS: Pneumonia was reliably produced in animals receiving either 10 or 100 cfu of type 3 pneumococci, with 30% and 50% mortality respectively. Similarly, with type 6B, the likelihood of pneumonia increased with the inoculum, as did the mortality rate. Prophylactic administration of a preparation of high-titered anticapsular antibody prevented the development of type 3 pneumonia and death. CONCLUSION: We propose that this model may be useful for the evaluation of vaccines for the prevention of pneumococcal pneumonia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hematoxylin-Eosin stain preparation of lung sections (original magnification 100×) obtained from autopsied rats following injection with a low (100 cfu per injection, panel A), medium (1000 cfu per injection, panel B) and high (10,000 cfu per injection, panel C) inoculum of type 6B pneumococcus in 0.5% low melting-point agarose. As the size of the inoculum increases, there is a clear progression from normal-appearing lung, focal pneumonia and diffuse pneumonia. Shown are 3 slides from a representative experiment.

References

    1. WHO meeting on maternal and neonatal pneumococcal immunization. Wkly Epidemiol Rec. 1998;73:187–188. - PubMed
    1. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group [In Process Citation] Pediatr Infect Dis J. 2000;19:187–195. doi: 10.1097/00006454-200003000-00003. - DOI - PubMed
    1. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20:1105–1107. doi: 10.1097/00006454-200112000-00002. - DOI - PubMed
    1. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I [In Process Citation] Clin Infect Dis. 2000;30:100–121. doi: 10.1086/313608. - DOI - PubMed
    1. Frimodt-Moller N. The mouse peritonitis model: present and future use. J Antimicrob Chemother. 1993;31 Suppl D:55–60. - PubMed

LinkOut - more resources